By just about any reasonable standard,
Roche (OTCQX:
RHHBY)
is an exceptional pharmaceutical and diagnostics company. Through
internal efforts and acquisitions large and small (particularly
Genentech), Roche has become one of the largest players in oncology,
with particular strength in biologics. That strength has in turn led to
double-digit free cash flow growth over the past decade and solid recent
share price performance.
As a shareholder, though, I'm starting
to get a little concerned by some of the changes at and around Roche. I
might be making mountains out of mole hills, but I also remember what a
mentor told me when I joined the buy-side in my mid-20's, "Your job now
is to be a professional worrier; it's the things you don't worry about
and check out that will bite you in the
". With that in
mind, while I see a lot of positives at Roche that merit ongoing
ownership, the direction of the firm does leave me more willing to
consider selling the shares.
Continue reading here:
Is Roche At Risk Of Losing Its Way?
No comments:
Post a Comment